As tariff threats and FDA staff cuts thrust the biopharma world into uncharted waters, President Donald Trump is offering the ...

With former director of the FDA’s Center for Biologics Evaluation and Research Peter Marks, M.D., Ph.D., out of the picture, ...

In the first meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) ...

GSK has been found guilty of bringing discredit on the pharma industry after a complainan | GSK has been found guilty of ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

After exploring a rival buyout offer worth 50% more than its first, bluebird bio is back where it started. | After striking ...

Pharma companies are leveraging the United States’ threat of tariffs on drug imports to push for policy changes in the EU. | Pharma companies are leveraging the Trump administration’s threat of ...

An investigation into the national security implications of pharma imports has been underway for two weeks, the Trump ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the ...

Ever since President Donald Trump nominated Robert F. Kennedy Jr. | In a Friday speech to FDA employees, the HHS secretary ...

Despite President Donald Trump’s threat last week that tariffs on pharmaceuticals will come “very shortly,” the biopharma ...